» Articles » PMID: 30216655

A Pan-cancer Atlas of Cancer Hallmark-associated Candidate Driver LncRNAs

Overview
Journal Mol Oncol
Date 2018 Sep 15
PMID 30216655
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Substantial cancer genome sequencing efforts have discovered many important driver genes contributing to tumorigenesis. However, very little is known about the genetic alterations of long non-coding RNAs (lncRNAs) in cancer. Thus, there is a need for systematic surveys of driver lncRNAs. Through integrative analysis of 5918 tumors across 11 cancer types, we revealed that lncRNAs have undergone dramatic genomic alterations, many of which are mutually exclusive with well-known cancer genes. Using the hypothesis of functional redundancy of mutual exclusivity, we developed a computational framework to identify driver lncRNAs associated with different cancer hallmarks. Applying it to pan-cancer data, we identified 378 candidate driver lncRNAs whose genomic features highly resemble the known cancer driver genes (e.g. high conservation and early replication). We further validated the candidate driver lncRNAs involved in 'Tissue Invasion and Metastasis' in lung adenocarcinoma and breast cancer, and also highlighted their potential roles in improving clinical outcomes. In summary, we have generated a comprehensive landscape of cancer candidate driver lncRNAs that could act as a starting point for future functional explorations, as well as the identification of biomarkers and lncRNA-based target therapy.

Citing Articles

Identification of a cancer driver gene-associated lncRNA signature for prognostic prediction and immune response evaluation in clear cell renal cell carcinoma.

Pan J, Hu D, Huang X, Li J, Zhang S, Li J Transl Cancer Res. 2024; 13(7):3418-3436.

PMID: 39145048 PMC: 11319985. DOI: 10.21037/tcr-24-127.


Long Non-Coding RNAs as "MYC Facilitators".

Garcia-Caballero D, Hart J, Vogt P Pathophysiology. 2023; 30(3):389-399.

PMID: 37755396 PMC: 10534484. DOI: 10.3390/pathophysiology30030030.


LncRNA NR2F2-AS1 functions as a tumor suppressor in gastric cancer through targeting miR-320b/PDCD4 pathway.

Luo M, Deng S, Han T, Ou Y, Hu Y Histol Histopathol. 2022; 37(6):575-585.

PMID: 35048354 DOI: 10.14670/HH-18-429.


Multiomics Analysis of Neuroblastoma Cells Reveals a Diversity of Malignant Transformations.

Narmonte M, Gibas P, Daniunaite K, Gordevicius J, Kriukiene E Front Cell Dev Biol. 2021; 9:727353.

PMID: 34557494 PMC: 8452964. DOI: 10.3389/fcell.2021.727353.


Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells.

Muluhngwi P, Klinge C Cancers (Basel). 2021; 13(14).

PMID: 34298743 PMC: 8307416. DOI: 10.3390/cancers13143530.


References
1.
Caldon C, Sergio C, Burgess A, Deans A, Sutherland R, Musgrove E . Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1. Cell Cycle. 2013; 12(4):606-17. PMC: 3594261. DOI: 10.4161/cc.23512. View

2.
Plaisier C, Pan M, Baliga N . A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers. Genome Res. 2012; 22(11):2302-14. PMC: 3483559. DOI: 10.1101/gr.133991.111. View

3.
Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S . Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science. 2015; 348(6237):880-6. PMC: 4471149. DOI: 10.1126/science.aaa6806. View

4.
Kong J, Sun W, Li C, Wan L, Wang S, Wu Y . Long non-coding RNA LINC01133 inhibits epithelial-mesenchymal transition and metastasis in colorectal cancer by interacting with SRSF6. Cancer Lett. 2016; 380(2):476-484. DOI: 10.1016/j.canlet.2016.07.015. View

5.
Hnisz D, Abraham B, Lee T, Lau A, Saint-Andre V, Sigova A . Super-enhancers in the control of cell identity and disease. Cell. 2013; 155(4):934-47. PMC: 3841062. DOI: 10.1016/j.cell.2013.09.053. View